statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The Law Offices of Frank R. Cruz announces an investigation of Abeona Therapeutics Inc. (Abeona or the Company) (NASDAQ: ABEO) on behalf of investors concerning the Companys possible violations of...

The Law Offices of Frank R. Cruz Announces Investigation of Abeona Therapeutics Inc. (ABEO) on Behalf of Investors

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Abeona Therapeutics announces employee inducement grants

CLEVELAND, April 01, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity...

Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Completion of FDA Inspections Marks Progress Towards PDUFA DateRelated Stocks: ABEO...

Abeona Therapeutics Inc (ABEO) Reports Full Year 2023 Financial Results

Q4 2023 Abeona Therapeutics Inc Earnings Call Transcript

This indicator may be signaling that ABEO's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Abeona Therapeutics (ABEO, $7) entered Downtrend as Momentum indicator drops below 0 level on Mar 18, 2024

- FDA completed Pre-License Inspection of Abeona's Cleveland manufacturing facility, as well as inspection of clinical trial sites for pz-cel pivotal Phase 3 VIITAL study -CLEVELAND, March 18, 2024...

Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections

This is a Bearish indicator signaling ABEO's price could decline from here. Traders may explore shorting the stock or put options...

Abeona Therapeutics (ABEO, $8.14) Moving Average Convergence Divergence (MACD) Histogram turned negative on March 14, 2024

This is a signal that ABEO's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Abeona Therapeutics (ABEO, $8.25) RSI Indicator left the overbought zone on March 07, 2024

CLEVELAND, March 05, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity...

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.

Volume	638,720.00
52-Wk High	$9.01
52-Wk Low	$2.83

ABEO Abeona Therapeutics Inc

About

Feed

News

Sentiment

Fundamentals